FMFuminori Moriyasu

Fuminori Moriyasu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fuminori Moriyasu has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination

    by Takao Itoi, Masahiro Sugimoto, Junko Umeda, Atsushi Sofuni, Takayoshi Tsuchiya, Shujiro Tsuji, Reina Tanaka, Ryosuke Tonozuka, Mitsuyoshi Honjo, Fuminori Moriyasu, et al.

    This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (n = 41) of different storage durations to identify metabolites showing high quantitative reproducibility, and subsequently analyzed all samples (n = 140). Overall, 189 metabolites were quantified and 66 metabolites had a 20% coefficient of variation and, of these, 24 metabolites showed significant differences among control, benign, and malignant groups (p < 0.05; Steel–Dwass test). Four multiple logistic regression models (MLR) were developed and one MLR model clearly discriminated all disease patients from healthy controls with an area under receiver operating characteristic curve (AUC) of 0.970 (95% confidential interval (CI), 0.946–0.994, p < 0.0001). Another model to discriminate PC from BTC and IPMC yielded AUC = 0.831 (95% CI, 0.650–1.01, p = 0.0020) with higher accuracy compared with tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), pancreatic cancer-associated antigen (DUPAN2) and s-pancreas-1 antigen (SPAN1). Changes in metabolomic profiles might be used to screen for malignant cancers as well as to differentiate between PC and other malignant diseases.


  • Dual red imaging (novel advanced endoscopy) can increase visibility and can predict the depth in diagnosing esophageal varices

    by Yoshihiro Furuichi, Takuji Gotoda, Fuminori Moriyasu, Saori Ogawa, Yoshitaka Kasai, Hirohito Takeuchi, Yuu Yoshimasu, Takatomo Sano, Katsutoshi Sugimoto, Takashi Kawai, et al.


  • Open Access

    Optimal injection rate of ultrasound contrast agent for evaluation of focal liver lesions using an automatic power injector: a pilot study

    by Katsutoshi Sugimoto, Fuminori Moriyasu, Hirohito Takeuchi, Mayumi Kojima, Saori Ogawa, Takatomo Sano, Yoshihiro Furuichi, Yoshiyuki Kobayashi, Ikuo Nakamura

    To determine the optimal bolus injection rate of ultrasound (US) contrast agent in vascular imaging for focal liver lesions. Thirteen patients with 13 focal liver lesions (5 hepatocellular carcinomas (HCCs) with cirrhosis, 4 liver metastases, 2 hemangiomas, 1 intrahepatic cholangiocarcinoma, 1 focal nodular hyperplasia) received two bolus injections of Sonazoid (at 0.5 and 2.0 mL/s) using an automatic power injector. The lesion-to-liver contrast ratio at peak enhancement was quantitatively evaluated. Enhancement of the lesions compared to liver parenchyma was assessed by two independent readers using a five-point scale and qualitatively evaluated by receiver operating characteristic (ROC) analysis. For all lesions, the contrast ratio was not significantly different between the two injection rates. For HCCs, the contrast ratio was higher at 0.5 mL/s (7.41 ± 6.56) than at 2.0 mL/s (4.28 ± 4.66, p = 0.025). For all lesions, the mean area under the ROC curve (AUC) was not significantly different between the two injection rates. For HCCs, the AUC was greater at 0.5 mL/s than at 2.0 mL/s (AUC: 0.86, p = 0.013). In contrast-enhanced US, an injection rate of 0.5 mL/s is superior to an injection rate of 2.0 mL/s for the quantitative and qualitative analysis of HCCs in the cirrhotic liver.


  • Sa1466 Usefulness of High-Intensity Focused Ultrasound (HIFU) Therapy for Unresectable Pancreatic Cancer

    by Atsushi Sofuni, Takao Itoi, Takatomo Sano, Fujita Mitsuru, Takayoshi Tsuchiya, Shujiro Tsuji, Nobuhito Ikeuchi, Reina Tanaka, Junko Umeda, Kentaro Kamada, et al.

  • Open Access

    Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study

    by Natsuhiko Shirota, Kazuhiro Saito, Katsutoshi Sugimoto, Kenichi Takara, Fuminori Moriyasu, Koichi Tokuuye

    Background: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). Methods: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15–74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm2. The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared. Results: The DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10−3 mm2/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment. Conclusion: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.


  • A case of Acute Duodenal Diverticulitis with an Enterolith treated with endoscopic therapy

    by Maya Suguro, Kei Yamamoto, Yuri Fukazawa, Hideaki Tanabe, Akira Madarame, Mami Takeuchi, Koichi Tabei, Fuminori Moriyasu


  • High intensity focused ultrasound (HIFU) therapy for pancreatic cancer

    by Fuminori Moriyasu, Atsushi Sofuni, Takatomo Sano, Mitsuru Fujita, Takao Itoi

    • 1 March 2015
      • p. 557-60

    [Current algorithm for the management of gallbladder cancer].

    by Takayoshi Tsuchiya, Takao Itoi, Fuminori Moriyasu

  • Open Access

    Case study to assess the safety of irreversible electroporation near the heart

    by Katsutoshi Sugimoto, Fuminori Moriyasu, Hirohito Takeuchi, Mayumi Ando, Takatomo Sano, Toshifumi Mori, Yoshihiro Furuichi, Yoshiyuki Kobayashi, Ikuo Nakamura

    Irreversible electroporation (IRE) is a promising technique for the focal treatment of soft tissue tumors. Even though the local application of an excessive electric field is a potential cause of cardiac arrhythmias, initial clinical studies have shown that IRE is generally safe when cardiac gating is employed. In this case report, we observed an episode of ventricular extrasystoles without hemodynamic changes during which time the synchronization device failed to operate properly, with pulses delivered not in the absolute refractory period but in the relative refractory period. At present, persons performing IRE must keep in mind that there is a small but real risk of synchronization failure even when a cardiac synchronization device is used. It is advisable to err on the side of caution when treating lesions near the heart.


  • Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease

    by Yoshitaka Kasai, Fuminori Moriyasu, Kazuhiro Saito, Takeshi Hara, Yoshiyuki Kobayashi, Ikuo Nakamura, Katsutoshi Sugimoto

    To assess the value of shear wave elastography (SWE) for predicting the presence of hepatocellular carcinoma (HCC) and esophagogastric varices (EGV) in patients with chronic liver disease. Liver tissue stiffness, as well as various other parameters potentially associated with HCC and portal hypertension, was measured by SWE in 273 patients with chronic liver disease. Among these patients, HCC was present in 89 and absent in 184, and EGV were present in 16 and absent in 257. The diagnostic performance of liver tissue stiffness and other clinical parameters in predicting the presence of HCC and EGV was evaluated using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUROC). With regard to HCC, liver tissue stiffness was significantly higher in patients with HCC (18.65 ± 10.78 kPa) than in those without HCC (10.64 ± 8.04 kPa; P < 0.0001). Significant differences in patient age (P < 0.0001), albumin (P < 0.0001), platelet count (P < 0.0001), AFP (P < 0.0001), and DCP (P < 0.0001) were also observed between patients with and without HCC. Liver tissue stiffness showed the largest AUROC (0.791). With regard to EGV, liver tissue stiffness was significantly higher in patients with EGV (22.65 ± 10.19 kPa) than in those without EGV (12.67 ± 9.45 kPa; P < 0.0001). Significant differences in albumin (P < 0.0001) and platelet count (P < 0.0001) were also observed between patients with and without EGV. Liver tissue stiffness measured by SWE is an independent factor for predicting the presence of HCC and EGV in patients with chronic liver disease.